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Abstract
Background: Low-dose Cisplatin and Interferon alpha treatment of solid tumors rarely has been
associated with severe hypocalcaemia. To the authors knowledge the phenomenon has not been
reported previously in patients with pancreatic carcinoma.
Case presentation: A patient with resected adenocarcinoma of the pancreas was treated with
adjuvant radio-chemo-immunotherapy using a combination of low-dose Cisplatin, 5-Fluorouracil
and Interferon alpha together with external beam radiation. Severe hypocalcaemia without signs of
acute renal failure or electrolyte disturbance occurred within 2 days at the 4th week of treatment
and required intensive care treatment.
Conclusion: Combination of biological and cytotoxic therapies may increase the incidence of
severe hypocalcaemia in pancreatic cancer. Oncologists should remain attentive of this problem as
more highly active regimes become available.
Background
Hypocalcaemia is a known side-effect in high-dose Cispl-
atin chemotherapy of solid tumors [1,2]. In the classic
case, hypocalcaemia is caused by excessive urinary loss
and decreased renal up-take during high-dose Cisplatin
treatment. Proximal tubular damage leads to decreased
reabsorption of cations. Acute nephrotoxicity presents
with increased creatinine and persistent protein and elec-
trolyte losses. Chronic nephrotoxicity is characterized by a
decrease of glomerular filtration rate and a slightly ele-
vated but persistent magnesium, potassium and calcium
excretion [3]. Hypomagnaesemic induced hypocalcaemia
is caused by inhibition of parathyroid hormone secretion,
impaired calcium release from the bones and low tissue
responses to PTH due to low magnesium levels. Cisplatin
associated hypocalcaemia and hypercalciuria can not be
influenced by calcium supplementation. Correction of
magnesium blood levels usually should improve the
hypocalcaemia [4]. Hypocalcaemia may be associated
with tetany, depression, carpopedal spasm, neuromuscu-
lar excitability, cardiac arrythmias with prolonged Q-T
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interval and sudden death, making it a true oncological
emergency [5].
Outside cytotoxic therapy hypocalcaemia has been
observed after thyroid and parathyroid surgery, chronic
renal failure, acute rhabdomyolysis and pancreatitis [6-9].
Cisplatin is often used in combinations with other agents.
Up to date, treatment of solid tumors increasingly consists
of a combination of chemo- and immunotherapy. Com-
bined use of Cisplatin, Interferon alpha and other chemo-
therapeutic agents is applied in head and neck, renal,
bladder, esophageal and pancreatic cancer [10-13]. How-
ever low-dose Cisplatin combined with biological Inter-
feron-alpha therapy has previously not been associated
with severe hypocalcaemia in patients with pancreatic
cancer.
We report on several cases of severe hypocalcaemia after
low-dose Cisplatin, 5-FU and Interferon alpha therapy
(CapRI) and review the literature [14].
Case presentation
Starting in August 2004 up to the present we have
assigned 47 patients with pancreatic cancer within a pro-
spective randomized study according to the CapRI sched-
ule, including 23 patients treated with a multimodality
concept consisting of low-dose Cisplatin (30 mg/m2), 5-
FU, Interferon alpha and external beam radiation. Before
the treatment all patients had undergone complete resec-
tion of a histologically proven adenocarcinoma of the
pancreas. The median age was 60 years, 29 patients were
male and 18 female. All patients had a Karnofsky score
above 70%, had pre-treatment laboratory values of Hb
>9.0 g/%, WBC >3000 cells/mm3, platelets >75.000 cells/
mm3, creatinine <1.5 mg/dl and bilateral renal function
determined by abdominal CT. None of them showed
signs of acute infection or was diagnosed with a severe
nonmalignant disease. Informed consent was obtained
from all of the patients. 15 of 23 patients treated with
radio-chemo-immunotherapy developed a moderate to
severe hypocalcaemia defined as Ca2+-levels below 1.9
mmol/l, 8 patients were asymptomatic.
Here, we report as an example the case of a 63 year old
man with a history of chronic pancreatitis presented with
recurrent jaundice in September 2004. An ERCP revealed
mechanical cholestasis and an endoprothesis was placed.
MRI imaging demonstrated a big mass in the head of the
pancreas highly suspicious for pancreatic carcinoma. A
pylorus preserving Whipple operation was performed and
pathology disclosed a poorly differentiated ductal adeno-
carcinoma. The tumor infiltrated the duodenum and por-
tal vein and invaded lymphatic vessels. Staging imaging
revealed no visible visceral or pulmonary metastases or
lymph node involvement. In November 2004 adjuvant
radio-chemo-immunotherapy according to the CapRI
schedule was administered after informed consent was
obtained. Treatment was initiated with radiation (50.4 Gy
over 6 weeks), Cisplatin 30 mg/m2 once a week, 5-Fluor-
ouracil continuous infusion 200 mg/m2/day and Inter-
feron alpha 3 MU subcutaneously 3 times weekly [14].
Four weeks after starting the treatment the calcium levels
declined within 2 days from 2.21 mmol/l to 1.64 mmol/l
(NR 2.1 – 2.65 mmol/l). Other electrolytes, creatinine,
urea and albumin were in the normal range. Oral substi-
tution with Calciumgluconate 1000 mg/day 3 times a day
was started. The patient was asymptomatic but com-
plained about diarrhoea 3 times a day. Despite medical
recommendation patient refused daily consultation and
i.v. drug administration or fluids. 6 days later he presented
with severe dehydration, tetany, paraesthesia and carpo-
pedal spasm. Trousseau's sign was positive and patient
collapsed in the outpatient department. An ECG showed
sinus-rhythm with prolonged Q-T interval (0.5 sec) and
ST depression (>0.5 mm), blood pressure was 110/65
mmHg. Laboratory analysis revealed potassium of 2.4
mmol/l (NR 3.5 – 4.8 mmol/l), calcium of 1.28 mmol/l,
creatinine of 1.16 mg/dl (NR <1.3 mg/dl), urea of 23 mg/
dl (NR <45 mg/dl), albumin of 32.3 g/l (NR 30 – 50 g/l)
and protein of 53.7 g/l (NR 60 – 80 g/l). Magnesium level
was not measured at this time point. LDH was increased
but the other cardiac enzymes and TNT were normal. Cal-
ciumgluconate 10%, calcitriol 0.5 µg and potassium 40
mmol were administered twice daily. Intensive i.v. fluids
and monitoring were started and the patient was trans-
ferred to the intensive care unit. Chemotherapy and radi-
ation were discontinued at that time. Symptoms
improved slowly and there was no evidence of acute renal
failure. 4 days later ECG, hydration and electrolytes were
back to normal, but calcium was still low at 1.61 mmol/l.
I.v. and oral substitution was continued and four weeks
later the calcium level was 2.34 mmol/l. Chemotherapy
without Cisplatin and Interferon was started again accord-
ing to cycle 2 and 3 of the CapRI schedule, over the fol-
lowing weeks of treatment the calcium levels remained
within the normal range and the patient was asympto-
matic.
The consecutive analysis of 23 patients treated with the
CapRI schedule of combined radio-chemo-immuno-
thrapy revealed mild to severe hypocalcaemia and
hypomagnesaemia in 65% of the patients despite calcium
and magnesium supplementation. Starting at day 14 of
the therapy magnesium levels declined under normal
range values (NR 0.75 – 1.05 mmol/l) with a median
value of 0.65 mmol/l (SD ± 0.12 mmol/l). (Figure 1) The
serum calcium levels of these patients reached values
below the normal range at day 36 of treatment despite
either oral or i.v. substitution started when the y were
symptomatic with median levels of 2.04 mmol/l (SD ±BMC Cancer 2006, 6:128 http://www.biomedcentral.com/1471-2407/6/128
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0.21 mmol/l). (Figure 2) During the whole course of
radio-chemo-immunotherapy creatinine and albumin
levels of the patients were within the normal range levels
(median creatinine 0.66 ± 0.16 mg/dl, median albumin
40.8 ± 4.77 g/l). (Figure 3) Parathormone and 25-OH-
Vitamin D3 levels were normal or slightly elevated. In
addition to the reported patient, 6 patients with calcium
levels <1.9 mmol/l complained of paraesthesia and mild
tetany, 2 patients showed signs of depression, mental irri-
tability and perioral numbness whereas 8 patients with
calcium levels between 1.9 and 2.1 mmol/l were asymp-
tomatic. (Table 1) 8 of the 15 patients with detected
hypocalcaemia and hypomagnesaemia were insulin
dependent diabetics. Compared to the non-diabetic
group the calcium level of these patients was lower with
median levels of 1.97 mmol/l (SD ± 0.21 mmol/l)
between week three to six. Magnesium levels were
decreased compared to the non-diabetic patients with
median values of 0.58 mmol/l (SD ± 0.14 mmol/l). The
albumin concentration (median value 38.6 ± 5.3 g/l) was
comparable to the non-diabetic patients were as the creat-
inine level (median value 0.86 ± 0.2 mg/dl) was slightly
increased. In all patients normal calcium levels were
reached under i.v. and intensified oral therapy within 4
weeks of initial presentation.
Discussion
Although oncologists commonly observe mild hypocal-
caemia in high dose Cisplatin therapy, severe hypocalcae-
mia has not been associated with low dose Cisplatin
treatment. Furthermore, review of the literature shows
that hypocalcaemia has yet not been reported in patients
with pancreatic carcinoma independent of the type of
chemotherapy.
The patients reported on here received a novel, highly
active treatment regimen by combining biologic and cyto-
toxic therapies. Picozzi et al. at Virginia Mason Medical
Center demonstrated a prolongation of disease free and
median survival with this approach [11,15].
Prior to the patient's treatment there have been no signs
of electrolyte disturbance, up until the third week of treat-
ment electrolytes were stable within the normal range.
Despite kidney protection in the form of intensive hydra-
tion before and after Cisplatin administration severe
decrease in calcium levels were observed within 48 hours
after the fourth weekly dose without any sign of acute
renal failure. At the time of therapy there was no evidence
of tumor burden in these patients so hypocalcaemia due
to tumor lysis syndrome could be excluded. The albumin
was within the normal range in all patients during the
whole therapy which excludes artificially low calcium
concentrations due to a decrease of measurable protein-
bound calcium fraction. However the incompliance of the
reported patient might have aggravated the severity of the
electrolyte disturbances. This implies that intensive medi-
cal advice is necessary to address the problem to the
patients and the attending physicians.
Under normal conditions concentrations of calcium are
highly modulated by the interplay between parat hor-
mone (PTH), calcitonin and vitamin D. In hypocalcaemic
conditions parat hormone and 25-OH-Vitamin D3 are
upregulated. In our study population PTH and 25-OH-
Vitamin D3 were slightly increased or normal during the
hypocalceamic phase, a significant drop in PTH levels
which might be causal for the hypocalceamia was not
seen. Distal renal tubular damage by Cisplatin probably
induces hypomagnesaemia due to DNA binding and
genetic alteration of the magnesium transport [16,17].
Magnesium normally interacts with distal tubular calcium
receptors increasing the reabsorption of both calcium and
magnesium. Low serum concentrations of calcium will
normally activate PTH excretion, but the increased gas-
Boxplott of Calcium serum levels Figure 2
Boxplott of Calcium serum levels. Day 1 after start of ther-
apy to day 42.
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Boxplott of Magnesium serum levels Figure 1
Boxplott of Magnesium serum levels. Day 1 after start of 
therapy to day 42.
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trointestinal calcium up-take will be insufficiently in nau-
seated or vomiting patients. This and low tissue responses
to PTH due to low magnesium levels might be responsible
for severe hypocalcaemia in patients with pancreatic can-
cer treated with the CapRI scheme.
In 1979 Hayes et al. reported for the first time tetany in a
series of 22 children with solid tumors under treatment
with high dose Cisplatin (90 mg/m2) [18]. The possibility
that the abnormalities reported were in part induced by
the Interferon alpha has to be discussed. The mechanisms
of nephrotoxicity induced by Interferon alpha are unclear.
However, mild proteinuria (25%), elevated serum creati-
nine (10%) and blood urea nitrogen (10%) were reported
by Jones et al. in 1300 patients treated with Interferon
alpha [19]. Intensive electrolyte wasting syndromes were
reported in patients with head and neck cancer treated
with Cisplatin (100 mg/m2), continuous 5-FU infusion
and escalating doses of Interferon alpha. Despite intensi-
fied supportive care and iv replacement 4 patients died
during phase one of the study from dehydration, diar-
rhoea and loss of electrolytes. Although these are known
side effects of high dose Cisplatin therapy Vokes et al. con-
cluded that Interferon and Cisplatin might have synergis-
tic toxic tubular effects [13]. At Virginia Mason, Picozzi et
al. did not report any hypocalcaemia using the same treat-
ment schedule as our group [13].
However, the sudden decrease in calcium levels in our
patients suggests that low dose Cisplatin toxicity alone
would be an unlikely explanation for the observed events.
Regarding the experience in other combined adjuvant
radio-chemotherapy for pancreatic cancer it seems that
radiation has no synergistic effect on Cisplatin-induced
hypocalceamia [20,21]. It is noteworthy that diabetic
patients were identified to be at significantly increased
risk of developing high levels of serum creatinine and
hypocalcaemia [13]. Patients after pancreatic surgery
often present with postoperative diabetes and represent a
high risk group for side effects during Cisplatin and Inter-
feron based chemotherapy. Diabetic patients presented in
our study with lower calcium and magnesium and
increased creatinine levels, what can confirm this hypoth-
esis. A decreased clearance of Cisplatin and Interferon due
to diabetic renal malfunction in these patients has to be
discussed as a reason.
Conclusion
Using this therapy approach the authors strongly recom-
mend intensive electrolytes monitoring and prophylactic
treatment of every patient with continuous oral calcium
and magnesium substitution starting at normal electrolyte
levels. In nauseated patients and patients with severe
dehydration, diarrhea or vomiting early i.v. fluid and elec-
trolyte administration have to be considered. In patients
with symptomatic hypocalcaemia and hypomagnesaemia
i.v. substitution is mandatory.
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Table 1: Symptoms and electrolyte values of symptomatic patients. Normal ranges: Calcium 2,1 – 2,65 mmol/l, Magnesium 0,75 – 1,05 
mmol/l, Albumin 30 – 50 g/l, Creatinine <1,3 mg/dl, *: out of range
Patient Symptoms Calcium Magnesium Albumin Creatinine
(mmol/l) (mmol/l) (g/l) (mg/dl)
1 tetany, carpopedal spasm, paraesthesia 1,28* ~ 32,3 1,16
2 paraesthesia 1,84* ~ 37,5 0,93
3 paraesthesia, tetany 1,84* 0,71* 30,1 0,82
4 paraesthesia, depression 1,8* 0,77 39,4 0,62
5 paraesthesia 1,62* 0,56* 32,3 0,71
6 paraesthesia, tetany 1,69* 0,29* 37,2 1,04
7 paraesthesia, depression 1,88* 0,42* 27,5* 0,7
Boxplott of Creatinine serum levels Figure 3
Boxplott of Creatinine serum levels. Day 1 after start of 
therapy to day 42.
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